← GLP-1

Version 1

Nov 9, 2026. Compare with the current version · Version history

GLP-1 (glucagon-like peptide-1) is a hormone made mainly in the gut and brain that boosts insulin release after meals and curbs appetite; drugs that mimic it, called GLP-1 receptor agonists, are used to treat type 2 diabetes and obesity.

What GLP-1 is

GLP-1 is a peptide, a short chain of amino acids. It is cut from a larger precursor protein, preproglucagon, which is also the source of the hormone glucagon. A 2019 review in Molecular Metabolism, written by 25 researchers in the field, notes that the precursor is expressed in pancreatic α-cells, in enteroendocrine L-cells throughout the gut, and in neurons of the brainstem's nucleus tractus solitarii, which are the primary source of endogenous GLP-1 in the brain. The L-cells line the intestine and release GLP-1 in direct response to luminal nutrients, meaning food passing through the gut.

GLP-1 is an incretin: a gut hormone that raises insulin secretion when sugar arrives by mouth. The idea is older than the hormone. The same review recounts that in 1906 Benjamin Moore reported easing the sugar in diabetic patients' urine with an extract of pig intestine, and that in 1929 Edgard Zunz and Jean LaBarre isolated a gut fraction that decreased blood glucose in experimental animals and named the supposed factor "incretin".

What it does in the body

The 2019 review lists the hormone's main metabolic effects as the glucose-dependent stimulation of insulin secretion, a decrease of gastric emptying (food leaves the stomach more slowly) and inhibition of food intake. It also lowers blood sugar by suppressing glucagon secretion, glucagon being the pancreatic hormone that raises blood sugar. "Glucose-dependent" matters: GLP-1 strengthens insulin release when blood sugar is high, rather than at all times.

It acts by binding the GLP-1 receptor, the target for the hormone in the pancreas, the brain and other tissues. The U.S. prescribing information for the drug Wegovy states that GLP-1 is a physiological regulator of appetite and caloric intake and that the receptor is present in several areas of the brain involved in appetite regulation.

The natural hormone does not last. The review gives its half-life as around 1–2 min, depending on the species: an enzyme in the blood, dipeptidyl peptidase-4 (DPP-4), clips two amino acids off its front end, and the kidneys clear what remains. That short life was the main obstacle to using GLP-1 as a medicine.

Discovery

GLP-1 was found through the genetics of glucagon. According to the Lasker Foundation's account of its 2024 award, Joel Habener's laboratory at Massachusetts General Hospital reported in 1982 that the fish glucagon gene encodes a predicted precursor protein (from the anglerfish) that held a second, glucagon-like sequence; in 1983 Graeme Bell found a similar peptide encoded in the hamster gene and named it GLP-1.

The precursor did not show which form of the peptide was active. Svetlana Mojsov, a peptide chemist, synthesised candidate forms, and in 1986 she, Habener and colleagues reported that a shortened form, GLP-1(7-37), exists in the intestine. In 1987, working with Gordon Weir, they showed it stimulated insulin secretion in rat pancreases, while the longer form was inert even at 10,000-fold higher concentrations. Jens Juul Holst's group in Copenhagen published related findings; the 2019 review lists their 1987 FEBS Letters paper, "Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut", among the founding studies. In 1992 the Boston researchers showed that GLP-1 prompts insulin release and lowers blood glucose in people, and in 1996 Stephen Bloom's group reported that injecting GLP-1 into the brains of rats reduced food intake.

From hormone to medicine

Two routes around the short half-life emerged. One came from a lizard. In 1992 John Eng and colleagues isolated exendin-4, a 39-amino-acid peptide, from the venom of the Gila monster (Heloderma suspectum), published in the Journal of Biological Chemistry. Its first 30 amino acids share ∼53% sequence homology to mammalian GLP-1, and a glycine at the second position protects the peptide from DPP-4-mediated degradation. A synthetic version, exenatide, was developed into the diabetes drugs Byetta and Bydureon.

A Gila monster, a lizard with beaded black and orange skin.
A Gila monster, a lizard with beaded black and orange skin.

Via Wikimedia Commons: Gila monster (Heloderma suspectum) by Theo Kruse / Burgers' Zoo, CC BY-SA 4.0.

The other route was to re-engineer human GLP-1. At Novo Nordisk, Lotte Bjerre Knudsen's team attached a fatty acid so that the drug binds albumin, a protein in the blood. The Lasker Foundation reports that this raised the half-life of the resulting drug, liraglutide, from 1.2 to 13 hours. Liraglutide was approved for type 2 diabetes in Europe in 2009 and the United States in 2010 (as Victoza), and for weight management in the United States in 2014 (as Saxenda). Semaglutide, a later molecule with a half-life of about 165 hours, was approved by the FDA for diabetes in 2017 (Ozempic) and for weight management in 2021 (Wegovy).

A third class of drug, the DPP-4 inhibitors, works the other way round: it blocks the enzyme so that the body's own GLP-1 lasts longer. The 2019 review traces how evidence that blocking DPP-4 preserved intact GLP-1 eventually led to the development of DPP-4 inhibitors for clinical use.

GLP-1 drugs for weight

The FDA's approval letter for Wegovy, dated 4 June 2021, approved it as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 or more, or of 27 or more with at least one weight-related condition such as high blood pressure, type 2 diabetes or abnormal blood fats. Its label states that semaglutide lowers body weight through decreased calorie intake, most likely through effects on appetite.

The Lasker Foundation's 2024 account summarises the trial results: in people with obesity but without diabetes, semaglutide at its weight-management dose produced an average loss of about 15 percent of starting weight; tirzepatide, a related drug from Eli Lilly, was approved for weight loss in 2023 with an average reduction of about 21 percent; and in placebo-controlled trials in people with cardiovascular disease, the drugs reduced the combined rate of cardiovascular death, heart attack or stroke by 20%. Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen received the 2024 Lasker–DeBakey Clinical Medical Research Award for the discovery and development of GLP-1-based drugs that have revolutionized the treatment of obesity.

Safety

The drugs' best-known side effects are digestive. As of the July 2023 revision, the Wegovy label lists the most common adverse reactions as including nausea, diarrhea, vomiting, constipation, abdominal pain, headache and fatigue, among others. Its warnings include acute pancreatitis and acute gallbladder disease, both seen in clinical trials.

The label also carries a boxed warning about thyroid tumours. It states that in rodents semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors, and that it is unknown whether the drug causes such tumours in humans, because the relevance of the rodent findings has not been determined. On that basis the drug is contraindicated, in the label's words, in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

Global guidance and access

On 1 December 2025 the World Health Organization issued its first guideline on these medicines for obesity. It makes a conditional recommendation that GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity, covering liraglutide, semaglutide and tirzepatide. The recommendation is conditional because of limited data on their long-term efficacy and safety, and a second, also conditional, recommendation on pairing the drugs with intensive behavioural programmes rests on low-certainty evidence.

The same release puts obesity at more than 1 billion people and links it to 3.7 million deaths worldwide in 2024. It notes that in September 2025 WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups, and it warns that, as of December 2025, the medicines were projected to reach fewer than 10% of those who could benefit by 2030.

Micwyn also has an entry on Semaglutide, the most widely known drug of the class.

This entry explains; it is not medical advice. Ask a doctor or pharmacist about your own health.

Sources